Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects.

[1]  J. Xing,et al.  Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination , 2014, Malaria Journal.

[2]  L. Decosterd,et al.  Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania , 2012, Antimicrobial Agents and Chemotherapy.

[3]  M. Turpeinen,et al.  Cytochrome P450 2B6: function, genetics, and clinical relevance , 2012, Drug metabolism and drug interactions.

[4]  M. Schwab,et al.  Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms , 2012, British journal of pharmacology.

[5]  D. Goodlett,et al.  Evaluation of P450 Inhibition and Induction by Artemisinin Antimalarials in Human Liver Microsomes and Primary Human Hepatocytes , 2012, Drug Metabolism and Disposition.

[6]  P. Siba,et al.  Pharmacokinetic Comparison of Two Piperaquine-Containing Artemisinin Combination Therapies in Papua New Guinean Children with Uncomplicated Malaria , 2012, Antimicrobial Agents and Chemotherapy.

[7]  P. Siba,et al.  Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Pharmacokinetic Study , 2012, Antimicrobial Agents and Chemotherapy.

[8]  D. Goodlett,et al.  Evaluation of CYPs inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes , 2012 .

[9]  T. Harrer,et al.  Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. , 2011, The Journal of antimicrobial chemotherapy.

[10]  J. Farrar,et al.  Orally Formulated Artemisinin in Healthy Fasting Vietnamese Male Subjects: A Randomized, Four-Sequence, Open-Label, Pharmacokinetic Crossover Study , 2011, Clinical therapeutics.

[11]  J. Lamba.  Pharmacogenetics of the constitutive androstane receptor. , 2008, Pharmacogenomics.

[12]  Oliver Burk,et al.  Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor , 2005, Molecular Pharmacology.

[13]  Anders Björkman,et al.  Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data , 2003, European Journal of Clinical Pharmacology.

[14]  M. Ashton,et al.  Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9 , 2003, Clinical pharmacology and therapeutics.

[15]  M. Ashton,et al.  Artemisinin Pharmacokinetics and Efficacy in Uncomplicated-Malaria Patients Treated with Two Different Dosage Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[16]  M. Ashton,et al.  Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. , 1999, British journal of clinical pharmacology.